Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without ...
At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
In late December, President-elect Donald Trump put pharmacy benefit managers ... regulators at Joe Biden’s Federal Trade Commission, which dropped a report just days before Trump’s ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with, the FTC said in a new report. The markups helped the pharmacy-benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback